Evidence map›Paper›PMID 36059252›Full record

ArticleLeukemia & lymphoma2022

MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.

Yue Wei, Hong Zheng, Pamela Pennington Lockyer, Faezeh Darbaniyan, Ziyi Li, Rashmi Kanagal-Shamanna, Kelly A Soltysiak, Hui Yang, Irene Ganan-Gomez, Guillermo Montalban-Bravo and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Allogeneic Transplant for CMML.Current hematologic malignancy reports · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yue WeiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2288-8405
Hong ZhengDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pamela Pennington LockyerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Faezeh DarbaniyanDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ziyi LiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rashmi Kanagal-ShamannaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7829-5249
Kelly A SoltysiakDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hui YangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Irene Ganan-GomezDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guillermo Montalban-BravoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelly S ChienDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6024-1613
Kim-Anh DoDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8710-7131
Naval DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-7103-373X
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3631-2482
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Statistical models for intratumor heterogeneity of tumor-infiltrated leukocytes in lung cancerR03CA270725 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, ZIYI · 2022 to 2023
$162k
NCI NIH HHS P30 CA016672NCI NIH HHS R03 CA270725
6 · The paper itself

Abstract

Failure of hypomethylation agent (HMA) treatments is an important issue in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Recent studies indicated that function of wildtype TP53 positively impacts outcome of HMA treatments. We investigated the combination of the HMA azacitidine (AZA) with DS-3032b and DS-5272, novel antagonists of the TP53 negative regulator MDM2, in cellular and animal models of MDS and CMML. In

Indexed as

Leukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesAnimalsAzacitidineImidazolesMiceThiazolesAzacitidineDS-5272ImidazolesThiazoleschronic myelomonocytic leukemiahypomethylating agentMDM2Myelodysplastic syndromesTP53

Identifiers

PMID36059252
PMCPMC10088064
OpenAlexW4294578747

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.